Agency Business briefs

Share this article:
Ignite Health named Matt Brown president. Brown, previously COO at the Irvine-based InVentiv shop, replaces Jackie Herr, who is retiring at the end of March.

Allergan named Pacific Communications agency of record for overactive bladder treatment Sanctura XR. The review resulted from a co-promotion agreement Allergan entered into with Quintiles whereby Quintiles will leverage its expertise in primary care to rapidly deploy a specialized sales force for the product while Allergan continues to target urology. Pacific will act as agency of record on both efforts.

InVentiv Health named former Pfizer exec Eric Sirota president of commercial services. Sirota, most recently VP US marketing, commercial strategy and innovation and regional sales within Pfizer's Powers business unit, will oversee InVentiv's Selling Solutions and Advance Insights divisions.

RelayHealth, a McKesson Corporation business, named Adair Greene McCann to handle strategic advertising and marketing support for its corporate identity and healthcare information technology offerings, including its health information exchange offering for hospitals and health systems.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?